Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2)
Status:
Active, not recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine if a drug called fluvoxamine can be used
early in the course of the COVID-19 infection to prevent more serious complications like
shortness of breath. Fluvoxamine is an anti-depressant drug approved by the FDA for the
treatment of obsessive-compulsive disorder. The use of fluvoxamine for the treatment of
COVID-19 is considered investigational, which means the US Food and Drug Administration has
not approved it for this use.
This study is fully-remote, which means that there is no face-to-face contact; study
materials including study drug will be shipped to participants' houses. People around the
United States and Canada can participate.
Phase:
Phase 3
Details
Lead Sponsor:
Washington University School of Medicine
Collaborators:
Covid-19 Early Treatment Fund Cures Within Reach McGill University Health Centre Department of Medicine Clinical Practice Assessment Unit